—BG Medicine also revived its IPO ambitions this week, after nixing an $80 million offering in January 2008. The Waltham, MA-based developer of molecular diagnostics is now proposing to raise as much as $86.3 million to help bring its test for heart failure to market in the U.S. and Europe.

—In non-IPO news, Westford, MA-based BioBehavioral Diagnostics raised $10 million in a Series B financing led by Sevin Rosen Funds and Tullis Dickerson. The startup intends to use the funds in part to expand sales and marketing efforts for a system used to diagnose attention-deficit hyperactivity disorder.

—Software maker Vivox of Natick, MA, raised $6.8 million in a third round of venture financing led by new investor IDG Ventures SF and joined by return investors Benchmark Capital, Canaan Partners, and GrandBanks Capital. Vivox’s technology allows gamers and inhabitants of virtual worlds such as Second Life, EVE Online, and EverQuest to talk with each other over the Internet.

—Lexington, MA-based 1366 Technologies, a developer of more efficient photovoltaic panels, nabbed $5.2 million in a Series B financing round, according the company’s president, Frank van Mierlo. North Bridge Venture Partners and Polaris Venture Partners provided $5 million of the funds and members of 1366’s management provided the rest, van Mierlo said.

—Tepha, a Lexington-based maker of polymers for medical applications spun off by Cambridge-based Metabolix (NASDAQ:MBLX), raised $3 million in an equity financing, according to an SEC filing. The deal could eventually total $7.4 million, the filing indicates.